Endonovo Therapeutics Inc (ENDV)

[Craig305]

Unrestricted shares increased by 11.7%
Going to be harder for people to get back to a higher share price with the float increasing at this high rate.

[Craig305]

Annual Report posted.
No $300K sales as stated in PR.
Donald Calabria...former COO of Endonovo is involved in Pulse and getting shares of ENDV to support a fake company.

Interesting how you can now see who is being given shares of stock in this Annual report.

At least ENDV will not end up on the Expert Market now.

[Craig305]

Based on a paid marketing article that was released by ENDV, there is a paragraph that states the following:

With the sale of the human medical rights and SofPulse® IP to SofPulse, Inc., Endonovo will turn its attention to other promising opportunities. Management intends to utilize groundbreaking multi-coil technology for over the counter PEMF product development in wellness and non-medical human markets while continuing to build their mergers and acquisitions division adding new IP and technology.

Wonder if this means ENDV will try to buy Micro-Pulse which is owned by Robert Dennis. Robert worked with Donnie Rudd on various projects in the past. Micro-Pulse has multi-coil products.
Of course this can only happen if ENDV can manage to raise funds with any of their capital raise offerings.

[Craig305]

Remember this announcement in the October 2021 letter to shareholders:

The Stanford University Clinical trial is being completed by Board certified Orthopedic surgeon Geoffrey Abrams, MD and is titled, “Pulsed Electromagnetic Field (PEMF) Therapy for Post-operative Pain”, is in recruitment stage with scheduled completion date of August 2023.

The completion date is now estimated at February 2025.

Goalpost has been moved a few times already.

[Craig305]

Donald was most certainly listed as part of Endonovo's team on their website for a few years. Just forget what title he was assigned.

[Craig305]

After more research, I see Pulse Therapeutics is a company with the officer of said company being Donald Calabria. It has the company address to his apartment in California.
Who is Donald Calabria?
He is an old friend of Alan's and can be found in the Hanover 10Qs receiving stock compensation for consulting services. I thought he might have also been involved with ENDV in the early stages. Can't remember now.
Point is....Pulse is not some independent company. Alan is most certainly behind the scene with Pulse and using that company for PR purposes to make it appear things are better than they really are.

[Craig305]

On Jan 26, 2023 ENDV released this PR
https://www.otcmarkets.com/stock/ENDV/news/Endonovo-Partners-with-International-Distributor-for-SofPulse-Line?id=387747

Coincidentally enough, that is the same day Pulse Therapeutics Technology became an operating company.
Most likely a company Alan or Ira coordinated into existence.

We have yet to see the $300k order hit the revenue of ENDV's financials. Will it show in the upcoming Annual? Will ENDV post the Annual?

If the testing and marketing of the initial $100k was so successful as of Jan 26, 2023....what have they been doing in the first 3Qs for the $300k order to not show up?

Follow the pattern....promises... positive news.....never actually materializes later.

I'm throwing out the challenge. Do due diligence on Pulse Therapeutics Technology and find out what they actually do or have done with Sofpulse. Find someone in MX or Costa Rica that is buying from them.

[Kjv]

I am in Canada so I can buy anything.

[Craig305]

Do you know if some brokerages (i.e. Schwab) stop allowing you to buy Pink Limited status stocks?

[Kjv]

Yup.
Saw that overnight

[Craig305]

ENDV is now changed to Pink Limited status on OTC Markets.

[Kjv]

Nah.

You don’t know me man.

[John_Vallay]

Kjv

Based on your reply, it would seem to me that you are looking for lightning to strike.
Your investment is based on impulse and dreams, not fundamentals.

You buy $10,000 worth of ENDV stock at .002 a share means you own 5 million shares.
If the stock reaches JUST 1 PENNY A SHARE, your 5 million shares are worth $50,000 which means you would be happy with a $40,000 profit.

You may also dream of the stock reaching 2 cents a share because it was close to 2 cents a year ago, which would mean your 5 million shares would be worth $100,000 and you net a $90,000 profit.

I do not wish you ill-will, but the chances of ENDV going to 0001 is much more probable than getting to your dream numbers.

Unfortunately in the OTC sub penny world, many investors have your philosophy and get burned most of the time, but maybe you will catch the lighting in a bottle and walk away a happy person with your ENDV investment, but in my opinion you are better off going to Las Vegas and putting your $10,000 on a HARD 8.

[Kjv]

Thank you.

I agree with your analysis and I do see it.

I have invested just enough to reflect I am just riding my luck.

We will see.

[Craig305]

The main people posting negative have been following this company since 2017.
This is not as simple as being sour grapes of buying high and never seeing a positive return.
There is a history of nothing ever being accomplished after positive and promising PRs are released to shareholders.
I believe John's challenge to you is to provide something positive about ENDV as a company and not just having luck on day trading.
If you believe the PRs of future catalysts are a positive....then good luck to you. No forward promises of the past have ever come to fruition with this company.
One needs to really analyze these future catalysts and determine how it will be possible to come true. Watch and see if any of the timelines actually get met.

[Kjv]

Been playing this for a while and I always recognize those bought high before a deep downward trend are more likely to point out the negatives

I have plays I bought high too and see how others are getting way cheaper!

Done some DD and taken my risk down here…we will see.

I appreciate you guys’s posts on here though…helped a lot!

[John_Vallay]

To Kjv

Did you write "It's not all doom and gloom"

What do you see as a positive. I am giving you an opportunity to say positive things about Endonovo the company and ENDV the stock.
While I am not going to engage in a confrontational message board back-and-forth with you, I am simply going to read your positivity about ENDV and not reply. Just looking for some reading here.

[Kjv]

Sorry I meant to say annual report.

Calling it 10K can be misleading. Companies just started to release annuals…so we will see.

It’s not all doom and gloom

[Craig305]

You might not call it an official 10K anymore, but an annual report is needed by OTC Markets if ENDV wishes to remain "current" status.
See requirements below.


Ongoing Requirements: To qualify for Current Information on an ongoing basis, companies must:
Publish reports through OTCIQ on the following schedule:
Quarterly Report within 45 days of the quarter end
Annual Report within 90 days of the fiscal year end
Attorney Letter within 120 days of the fiscal year end if financial statements are unaudited.
Maintain a Verified Profile. At least once every six months, review and verify the Company Profile through OTCIQ.
Maintain Transfer Agent Verified share data. If your transfer agent participates in the Transfer Agent Verified Shares Program, then your securities must have current share data verified by the transfer agent.
Maintain an Active standing in the Company’s State of Incorporation.


Pink Limited Information Tier
Companies that do not meet the requirements of the Pink Current Information tier set forth above may still qualify for the Pink Limited Information Tier by meeting the following minimum disclosure requirements.
Annual Financial Statements: Publish one set of Qualifying Annual Financial Statements which cover the past 2 completed fiscal years, provided the most recently completed fiscal year is within the past 16 months.

[Kjv]

You don’t file 10K if you are alternative reporting.
Form 15 was to stop SEC reporting.

So the next filing is quarterly not behind yet!

[Craig305]

ENDV still has to file 10k to remain compliant with OTC Markets standards.
They are now late.
Let's see how long it takes for Pink Limited status to appear.

[John_Vallay]

KARMA

That is the only thing I will say when thinking about Alan Collier

KARMA in one form or another will get Collier. Maybe it will be KARMA against Collier directly, or a loved one like his children or family member.

Collier can steal from people and he may think he is getting away with it, but at some point KARMA will get Collier through afflicting a loved one.

I know KARMA scares me even more than a jail cel. Most people are good people and do the right thing for many reasons, but ask psychiatrists and psychologists and they will tell you even good people need FEAR to dissuade them from doing something wrong or illegal.

Sometimes FEAR is the possibility of jail, embarrassment and sometimes KARMA. For me I like to think being just a good person is what makes me tick, but at times KARMA is what scares me the most. KARMA against my wife and especially against my kids is what keeps me on the straight and narrow.

Who knows the truth behind closed doors inside Colliers house or with his children now or in the future, but KARMA should be in Colliers mind if he has a soul.

[Craig305]

Look at this dated website. Has an accusation against Collier for something prior to Endonovo.

https://www.ripoffreport.com/reports/greenbridge-capital-alan-collier-mark-chasan/los-angeles-california-90064/greenbridge-capital-alan-collier-mark-chasan-ppm-deals-are-fraud-ripoff-dishonest-raise-ca-258999

This response is interesting:
"Original poster told the truth. Retraction was not his but written by the accused firm. Check out Alan Collier at Nevada corporations site. He forms new LLCs all the time to cover his tracks and then pretends in California that they are employers when it is all his own LLCs formed with his buddy Garry Kann. Latest one formed on 5/4/09 as Kann Collier & Company. The scam and con has been going for almost 20 years in one form or another. Craig's original post is correct."

I am not the Craig referenced in this post...LOL

Should raise an eyebrow that Gary Kann is affiliated with ENDV and has NO accomplishments since being PR'd exactly 2 years ago. Where are the profitable companies he was acquiring for ENDV portfolio?
The news of concrete and other construction companies are now swept under the rug. No mention of why the promised LOIs never materialized. They expect the shareholders to forget and just keep accepting other fluff PRs.

That response from 2009 appears to still hold water.

[John_Vallay]

If we do not see Alan Collier on AMERICAN GREED within 5 years I would be surprised.
He is a sociopath
He is someone that would rather steal than get a job
And the most dangerous and sad thing about him - He probably believes everything he is saying.

Disturbing that people do not conduct their own due diligence on Alan Collier. His approach is very similar to the ponzi scheme Alan Harper had on Two and a Half Men.

[Craig305]

With the form 15 in effect, Collier can sell his shares without filing form 4 disclosing his stock selling. Let's see how many of the Restricted shares converted in the next share structure update.

[Craig305]

Have you looked at the latest PR for ENDV?
Did you ever invest in the original Reg A?
Check out this website.
https://www.invest-sofpulse.com/
You believe Sofpulse will be able to raise capital and actually make it to NASDAQ?

[MAGA_PATRIOT]

Thx. Agreed. I'm on the same page, but I saw your name/post and remembered you from back in the day, so was just curious.

I'm debating on throwing a few $K at this with the hope that they stop dumping into it, and allow it to spike back to .005-.008 before close of day, so I can flip a quick profit. However, the old days still have me turned off, which is why I haven't pulled the trigger yet.

Anyway. Thx and hope all is well....

[Craig305]

How can something bought for $4.5M, years ago, with practically no sales, now be worth $50M?
Collier has "intended" to do many things in the past and has never accomplished or followed through with any of them. Just look at every news PR in the past. What has actually ever been accomplished per the past PRs. I can't think of any.
Is now going to be any different?
How many times are people going to allow him to keep moving the goalposts and forgetting/forgiving the empty promises?

This stock is for day trading only. Is certainly not a long term investor hold. Collier has no respect for shareholders or compassion for the $ they lose on this stock. It is all about self enrichment for himself.

[MAGA_PATRIOT]

Hey Craig - What are your thoughts on this? I was invested here back in 2017 with you, Seaheck, brojazzy, etc.... and took a substantial hit because of these guys. Then they rs'd in 2019.

Is this just another one of mgmt's games or this for real? If it's for real, $50M is roughly 65X current MC.

The wording of this statement is what it's holding me back from taking another position here:

with its present intention is to distribute 80% of such shares to ENDV shareholders on a date to be determined.

Anyway, just wondering what your thoughts on all of this are?

[Cornerstone_Marketing]

80% will be distributed to current shareholder on the date announced - coming soon!

The other 20% will be used to satisfy existing debts and notes.

This is from a previous company release.

[jokerwild477]

what happens to the shares

[PStockPickz]

Huge news this morning

[Craig305]

Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
Endonovo Therapeutics, Inc.
Thu, March 28, 2024 at 9:03 AM EDT

Endonovo Therapeutics, Inc.
Los Angeles, CA, March 28, 2024 (GLOBE NEWSWIRE) -- Endonovo (OTC PINK: ENDV) and its subsidiary, SofPulse, Inc., today announced they have finalized and completed the Asset Purchase Agreement (APA), originally signed in December 2023, for the acquisition of Endonovo's assets and Intellectual Property (IP) for a minimum of $50 million.

With completion of the APA, both Endonovo and SofPulse, Inc. share a strategic vision and a commitment for long term growth.


Finalized Terms of SofPulse, Inc. Spin-off

The APA transaction for the purchase of Endonovo assets and IP by SofPulse, Inc. is now closed, pending the customary regulatory approvals.

Key points of the APA include:

Agreement to engage Adeptus, a qualified third party's asset valuation firm.

Acquisition of ENDV IP by SofPulse Inc., including FDA-clearance in the human medical markets, for $50 Million, with potential additional valuation determined by Adeptus (which management believes will be between $50 million to $100 million).

Agreement for SofPulse Inc. to issue $50 million in freely traded stock through an S-1 registration, priced at $5.00 per share to Endonovo.

Register and distribute SofPulse Inc. shares to ENDV's shareholders with its present intention is to distribute 80% of such shares to ENDV shareholders on a date to be determined.

Any additional valuation by Adeptus over $50 million will be paid in cash or in a secured promissory note which will be convertible into NASDAQ listed marketable securities at the sole discretion of the ENDV.

Filing of S-1 registration statement to register the assets being purchased and to fulfill the regulatory requirements for a NASDAQ listing following the sale's completion.


SofPulse, Inc. Capital Raise

SofPulse, Inc. has commenced its capital raise of up to $1,000,000 through a 506(c) -offering tailored for accredited investors. The present capital offering is valued at a pre-money valuation of approximately $25.2 million, with shares priced at $2.50 per share. The capital raise is anticipated to support further development and growth. Upon completion of the capital raise, SofPulse Inc. will look to further develop the assets and IP through additional capital funding rounds to fund its path toward its IPO and NASDAQ registration.

SofPulse Inc. Drives Revenue Growth with Expanded Distribution

SofPulse® Pulsed Electro Magnetic Field (PEMF) medical technology, utilizing its FDA-clearance for the reduction of pain and edema post-operatively, helps to position the Company as a leader in the development of innovative medical devices.

To drive revenue and future expansion, SofPulse, Inc. aims to build on current marketing distribution initiatives for long-term growth and stability in the following areas:

Development of Veterans Association (VA) and Department of Defense (DoD) post-operative pain management market for SofPulse®.

Expand distribution throughout Taiwan, building on Taiwan FDA clearance.

Increase expansion efforts into other Asian markets such as Singapore, South Korea, Thailand, and Hong Kong.

Grow International distribution of SofPulse® in Mexico, Central and South America.

Re-initiate efforts to penetrate European markets with SofPulse® devices.

Expand and develop SofPulse® devices and other new PEMF medical devices for commercialization to all US hospital, surgical and rehabilitation facilities.


Endonovo Market Outlook is Extremely Positive

The Endonovo management team is excited about the completion of the APA and looks forward to the continued growth and success of Endonovo Therapeutics, Inc. through the following areas of business:

Exclusive rights to develop non-medical human PEMF IP and wellness markets.

Development of new non-medical wellness products for the expanding U.S. PEMF therapy device wellness market.

Utilization of groundbreaking multi-coil IP technology for over-the-counter PEMF product development in wellness and human markets.

Maintenance of rights to develop comprehensive telehealth division and platform (SofPulse, Inc. has signed an exclusive agreement to be a customer with a five-year contract).

Continued focus on mergers and acquisitions division to enhance product offerings for new technology and IP.

Endonovo, as business continues to expand, offers additional value to shareholders with the development of the non-medical Wellness market and other opportunities planned by the Company to sustain its long-term growth

SofPulse® PEMF Benefits and Technology Featured in The Press

SofPulse®'s effective non-pharmacological PEMF pain and inflammation management solutions were highlighted in a recent article by Wallstreetpr.com, titled "Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)." The article can be found on MarketScreener, Barchart.com, abnewswire, Benzinga, Muck Rack, The Globe and Mail, and other news outlets.

Click to view article:
https://www.marketscreener.com/quote/stock/PACIRA-BIOSCIENCES-INC-7299436/news/Beyond-the-Pill-Athletes-Champion-PEMF-and-Non-Opioid-Solutions-for-Pain-Management-ENDV-46240551/

About Endonovo Therapeutics, Inc.

Endonovo Therapeutics is currently structured into three divisions- Legacy – a commercial stage developer primarily of medical and non-medical PEMF devices and products; and its Build Up Strategy – acquiring complementary new technology industries; and its Telehealth - focused on bringing Telehealth solutions to the commercial and medical markets. In 2023, Endonovo announced the sale of their medical division and related IP for $50 Million or higher, through an Asset Purchase Agreement (APA) to SofPulse, Inc.. SofPulse Inc., a current subsidiary of Endonovo and a proposed spin-off company through the APA, plans to coordinate the use of SofPulse® and continue to commercialize innovative medical devices globally.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate", "believe", "plan", "estimate", "expect", "intend" and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date after the date of this press release.

Investor Relations Contact:
Endonovo Therapeutics, Inc.
Steve Barnes
[e-mail]
www.endonovo.com





View comments

[Biotech_Tradez]

Look at the address listed. It is Wyoming. It also is the address for thousands of other corporations.

They are likely incorporating some umbrella companies in Wyoming for the company and its officer to avoid paying taxes on their gains from the spin out. Remember Collier has given himself millions of shares by granting a company he controls those shares. If you bought assets for $4.5m and sell them for "at least $50 MILLION" then you have a gain of millions. They are probably trying to avoid paying both state income taxes and personal income taxes of their free shares.

BTW. My last statement was not directed at you but at the people who continue to buy stock based on the lies ENDV is publishing as well as the stock promoters they hire.

[Biotech_Tradez]

ENDV is a SCAM!

Why would they fire them if they just got a bunch of new suckers to buy up all the shares they are selling? Publishing a bunch of lies is right in order with what ENDV does on a constant basis. As long as they are allowed to continue this fraud they will continue defrauding investors.

I have warned investors repeatedly that this was a penny stock scam for a few years. Pretty much everything I said was going to happen, happened. Back to sub penny and now delisted. ENDV management is just now trying to spin out the assets to fleece the investors while they make out like bandits with golden parachutes. If you buy this stock you deserve to lose your shirt. I no longer will bother to respond, I have exposed them enough and if you are too stupid to see it then this stock is the least of your worries.

[Craig305]

What do you think of this?

https://bizfileonline.sos.ca.gov/search/business

Type in Endonovo and you will see they ceased to be a for profit company on 2022 and then in 2023 registered as non-profit???

Saw a comment on Yahoo finance board.

Endonovo is also registered as a company in Delaware. This California change could be insignificant.

[Craig305]

Endonovo needs to fire this PR firm.

They are releasing a PR that was initially out in 2016 or sometime close to that year. 😄
Certainly is not applicable to now.

"has plans to apply for orphan drug designation for its next-generation, off-the-shelf treatment of Graft-Versus-Host (GvHD) disease, using enhanced stem cells from the human umbilical cord. If Endonovo receives FDA approval to market its product, the company could easily reach a billion-dollar valuation."


https://blog.doctorsbusinessnetwork.com/biotech-companies-stock-in-your-portfolio/?utm_source=dlvr.it&utm_medium=linkedin

[Craig305]

On the Sofpulse investor website, they are still referencing the 2018 valuation report of $75M.
Looks like the updated "true" valuation is never going to happen.

[Craig305]

All this volume and the SP can't surpass .0024.
Wonder how many shares are for sale by OTCN?

[Craig305]

Using the "preprogrammed" mode, SofPulse
automatically delivers 15 minutes of therapy every two hours, providing at least 8 full days of continuous treatment.

[gimmee greenbacks]

Thanks for the reply..how long is a “treatment”?
Or to put another way how many hours of continuous use is the battery good for?

[Craig305]

OTC Markets Update

Pink Current, AS: 2.5B, OS: 333M, US: 139M

Officer(s) Added:
🟢Steven Barnes, Vice President

[Craig305]

It is "rated" for 100+ treatments with the pre-programmed continuous auto cycle and 150+ with the manual use of it.
These are the official numbers released by the company but can go longer depending upon the quality of the battery.

[gimmee greenbacks]

Question: what is the battery life of the Sofpulse device? Thanks!

[retired early]

Ground Control to Major Tom
Your circuit’s dead, there’s something wrong
Can you hear me, Major Tom?
Can you hear me, Major Tom?
Can you hear me, Major Tom?

[Craig305]

Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions

March 04, 2024 09:09 ET| Source: Endonovo Therapeutics, Inc.Follow

US Army Medical Research and Development Command Vendor Day

Los Angeles, CA, March 04, 2024 (GLOBE NEWSWIRE) -- SofPulse Inc. -- a subsidiary of Endonovo (OTC PINK: ENDV) and a proposed spin-off company -- announced today the participation of its SofPulse® Pulsed Electro-Magnetic Field (PEMF) FDA-cleared medical device in the United States Army Medical Research and Development Command (USAMRDC) May 2024 Vendor Day.

The USAMRDC is the Army's medical materiel developer, responsible for medical research, development and acquisition. The command unit has a key role in identifying innovative pain management solutions for Veterans Administration (VA) and Department of Defense (DoD) patients and uses.

SofPulse®, along with its VA reseller, Academy Medical Inc., is planning to showcase SofPulse® and its non-evasive, drug-free pain management solution to the VA and military attendees. The Company will prepare videos, posters and printed materials to educate and demonstrate pain and inflammation reduction benefits of SofPulse® to attendees during the event.

Current SofPulse® Use and Plan for Growth in VA/DoD

Since 2019, SofPulse® has been used regularly by surgeons at the Michael DeBakey VA Medical Center in Houston to manage pain and edema following various cardiothoracic procedures. An investigator-initiated study, authored by Dr. Samir Awad, Professor of Surgery at Baylor College of Medicine, entitled “The Impact of Pulsed Electromagnetic Field (SofPulse®) on Postoperative Pain in Patients Undergoing Cardiothoracic Surgery” was accepted for oral presentation at the 44th Annual meeting of the Association of VA Surgeons in 2020. The results of the study demonstrate that the use of SofPulse® significantly decreased postoperative pain Visual Analog Scale (VAS) by 50%, decreased postoperative opioid requirements (morphine equivalent dose) by 70% and resulted in a significant decrease in Length of Stay at the hospital by a median of two days.

Ira Weisberg, President of SofPulse, Inc., said of the event: “Our goals are to increase distribution of SofPulse® throughout the entire VA/DoD health care system. This will allow our wounded warriors and veterans who served our country to recover with less pain and get back to their lives faster. We feel it is an honor that SofPulse® can embrace and be proud to be making a difference in the lives of our national heroes.”

SofPulse® Expands VA Marketing Efforts

As SofPulse® prepares for wider integration into the VA and DoD medical systems, SofPulse Inc. is planning to attend multiple VA-related pain management and surgical conventions and symposiums during 2024. In addition to being featured at the USAMRDC Vendor Day, the Company is planning to attend the 2024 Association of VA Surgeons (AMSUS) Society of Federal Health Professionals, Operational Medicine Symposium (OpMed) & Technology Showcase, Traumatic Brain Injury Conference, Military Surgical Symposium and the Special Operations Medical Association (SOMA) conferences.

Academy Medical Partnership Provides SofPulse® Path to Expand VA & DoD Use

Currently, SofPulse® devices are listed on both the prestigious Federal Supply Schedule (FSS) and the Distribution and Pricing Agreement (DAPA) by our distribution partner, Academy Medical Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB) government reseller. SofPulse® featured by Academy Medical at USAMRDC Vendor Day, offers extended exposure for the opportunity to present and demonstrate its innovative pain management solutions to multiple organizations at one time.

Weisberg, emphasized: “Our relationship with Academy Medical allows SofPulse® access to all VA and DoD medical centers nationwide to work with surgeons and staff to expand use. We are currently in several high-level discussions with various VA and DoD medical centers to initiate the use of SofPulse® at these centers. SofPulse® is being seen as a viable non-pharmacological pain management alternative for patients with both addictions to opioids and those susceptible to opioid abuse or opioid allergies. The expansion of the use of SofPulse® throughout the veterans and military healthcare systems is a top priority for our Company moving forward and can enable us to build continued market growth.”

VA Opioid Safety Initiative is Focused to Improve Pain Care Quality and Safety For Veterans

SofPulse, Inc., is committed to supporting the VA in its mission to provide high-quality, drug-free patient-centered care to veterans. The VA’s efforts to improve pain care quality and safety, such as the Stepped Care Model and the Opioid Safety Initiative, are central to the integration of SofPulse®, which offers a non-opioid pain management solution that complements existing strategies.

VA.GOV states: “The VA is committed to finding ways to manage pain in veterans while limiting the risks of long-term opioid therapy.”

In May 2022, the VA/DoD released their Clinical Practice Guidelines for the Use of Opioids in the Management of Chronic Pain to all VA Hospitals, Medical Centers, and medical providers. The report recommends medical providers assess both acute surgical and chronic pain experienced by patients regularly to discontinue or combine opioid pain management with non-opioid modalities such as devices and other drug-free options. Integrating SofPulse® into its post-operative pain management protocols, the VA can improve the quality of care and enhance the well-being of veterans nationwide.

[Craig305]

A lot of this selling must be due to conversion of restricted shares to common and then being sold.
You can see the lowering of restricted and increasing of common shares from the last financials to what is reported on OTC MARKETS.

[Biotech_Tradez]

This 8K is NOT a purchase order.

The Amendment, among other things, establishes performance thresholds which Evermed must meet to maintain its exclusive rights in Taiwan under the Agreement.

This is no different than the fake agreement they had with Magniant, as you previously mentioned. Magniant also had to meet certain targets in order to have exclusive rights, they never sold anything thus they lost exclusivity.

This isn't a $21 million purchase order. Merely a pathetic attempt by ENDV management to deceive its shareholders into buying its stock thinking that a $21 million order has been received or will be received. NOWHERE IN THIS 8K IS THERE A PURCHASE ORDER NOR A REQUIREMENT TO ORDER.

It is more proof that PennyStockSnipers aka CornerStone Marketing, or whatever other alias he operates under, is nothing more than a paid stock promoter pushing lies and deceptions. He is welcome to respond to my claim but won't without making excuses, shifting the goal post, or changing the topic.

[Craig305]

The $21 Million order is referring to the following 8K.
https://www.otcmarkets.com/filing/html?id=17161510&guid=Lud-kpqa-fczB3h

[Biotech_Tradez]

You are embarrassing yourself Jeff.

Down 80% since your pump began. Where is that 21 million dollar order? If there was one we would have seen it in a press release, after all ENDV management has no shame in putting out BS.

This ship is sinking and you are telling people everything is fine and dandy. Do everyone a favor and leave.